Study of GDX012 in Patients With MRD Positive AML

Inclusion Criteria: * ≥ 18 years old * Weight ≥ 40 kg * Anticipated life expectancy \> 3 months prior to lymphodepletion * Karnofsky Performance Score ≥ 70% * Histologically confirmed diagnosis of AML * In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted * MRD detected in bone marrow by MFC * Negative pregnancy test (females of childbearing potential only) * Agree to use effective birth control * Left ventricular ejection fraction (LVEF) ≥ 50% * Platelet Count ≥ 20 x 109/L * Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation) * Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation) * Hemoglobin ≥ 8.0 g/dL * Creatinine Clearance ≥ 40mL/min * Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin \< 35% of Total Bilirubin) * ALT ≤ 2.5 x ULN Exclusion Criteria: * Cytotoxic chemotherapy within 3 weeks * Immune therapy within 4 weeks * Immunosuppressive therapy within 2 weeks (with exceptions) * Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer * Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities * Known hypersensitivity to chemotherapy, other agents, or excipients used in this study * Female patient that is pregnant or lactating/breastfeeding * Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1 (with exceptions) * History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents) * Active CNS involvement (i.e. leukemic infiltration) * Any other malignancy that requires active therapy * Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months) * Active infection with HIV, Hepatitis B or Hepatitis C NOTE: other protocol defined inclusion/exclusion criteria may apply.